Results 231 to 240 of about 402,660 (356)

Redefining Parkinson's Disease management: the synergistic role of neurotrophic factors and mitochondria. [PDF]

Cell Mol Life Sci
Chang J, Li Z, Liu T, Cheng X, Wei J.
europepmc   +1 more source

Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. [PDF]

Front Pharmacol
Zhang Y, Bu Y, Song M, Hao Z, Chen J.
europepmc   +1 more source

Dopaminergic medication alters muscle synergy during sit-to-stand motion in Parkinson's disease. [PDF]

Front Neurol
Kikuchi K, Oyama G, Shimoda S, Hamada H, Aydin R, Kameyama Y, Sato K, Kitahara E, Kamiyama D, Yamashita A, Shimazu T, Fujiwara T, Hattori N, Qi A.   +13 more
europepmc   +1 more source

Genetic and Pathological Testing Attitudes for Parkinson's Disease in At‐Risk Relatives

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is increasingly recognized as a neurodegenerative disorder with a broad clinical spectrum and diverse biomarkers enabling early detection. α‐synuclein seed amplification assays (SAA) and genetic testing now allow identification of PD pathology in asymptomatic individuals.
Tal Weil, Anat Mirelman, Roy N. Alcalay, Nurit Omer, Penina Ponger, Avner Thaler   +5 more
wiley   +1 more source

Neuropsychological aspects of impulse control disorders in Parkinson's disease. [PDF]

Front Aging Neurosci
Scanferla L, Djamshidian A.
europepmc   +1 more source

Neuron-specific modulation of SLC30A10 identifies dopaminergic and glutamatergic neurons as targets of manganese-induced motor disease. [PDF]

Proc Natl Acad Sci U S A
Grant SM, Melkote A, Bernstein MX, Jursa T, Taylor CA, Hutchens S, Shawlot W, Zweifel LS, Gonzales RA, Smith DR, Mukhopadhyay S.   +10 more
europepmc   +1 more source

Early motor deficits, sleep dysfunction and reduction in dopaminergic neurons in a PARK7^-/- zebrafish larval model of Parkinson's disease. [PDF]

Sci Rep
Solheim N, Pinho BR, Oliveira NAS, Lima LP, Børve A, Oliveira JMA, Fladmark KE.   +6 more
europepmc   +1 more source

Linking GABAergic and Dopaminergic Neurotransmission: Effects on Neural Activity During Human Speech Control. [PDF]

Hum Brain Mapp
Battistella G, Simonyan K.
europepmc   +1 more source

Quantitative Assessment of Visible Nigrosome‐1 in Patients with Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background The nigrosome‐1 (N1) sign on susceptibility‐weighted imaging (SWI) typically disappears in Parkinson's disease (PD), though some patients can show uni−/bilaterally preserved N1. Objective Investigating whether visible nigrosomes in PD patients differ from those of healthy subjects (HC). Methods Forty‐eight PD and 35 HC underwent 3 T‐
Maria Eugenia Caligiuri, Ilaria Chimento, Marida De Maria, Emma Biondetti, Jolanda Buonocore, Valerio Riccardo Aquila, Maria Celeste Bonacci, Emanuele Tinelli, Umberto Sabatini, Aldo Quattrone, Andrea Quattrone   +10 more
wiley   +1 more source